Recent 8-K filings for FLGT

• June 1, 2026, 7:07 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026

  FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.

• May 21, 2026, 5:04 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS

  Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.

• May 1, 2026, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Fulgent Q1 2026: GAAP EPS -$0.80, revenue $71.1M, reiterates FY2026 guidance

  GAAP net loss of $24.8M ($0.80/share); non-GAAP loss of $11.0M ($0.36/share).

• March 17, 2026, 7:59 PM ET M&A materiality 0.70 neutral item 1.01item 2.01item 7.01item 9.01 ◈ M&A Transactions ×2

  Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash

  Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.

• February 27, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share

  Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.

• December 22, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01item 8.01item 9.01

  Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total

  Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.

• November 7, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Fulgent Genetics Q3 revenue $84.1M (+17% YoY), raises FY guidance, non-GAAP EPS $0.14

  Revenue $84.1M, up 17% YoY; raised full-year 2025 revenue guidance to $325.0M.

• October 20, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Fulgent reports Phase 2 FID-007 combo data: 51% ORR, PFS 7.8 months in R/M HNSCC

  Preliminary Phase 2 data for FID-007 + cetuximab in 1L-2L R/M HNSCC; 39 patients randomized.

• August 1, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Fulgent Q2 core revenue $81.7M (+16% YoY); raises FY2025 guidance to $320M

  Core revenue $81.7M, up 16% YoY; total revenue $81.8M.

• May 2, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Fulgent Q1 core revenue $73.5M (+16% YoY); GAAP loss $0.37/share; reiterates FY25 guidance

  Core revenue of $73.5M, up 16% YoY; GAAP net loss of $11.5M ($0.37 loss per share).

• February 28, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M

  Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.

• November 8, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Fulgent Q3 core rev $71.7M (+9% YoY), GAAP loss $0.48, non-GAAP EPS $0.31; guides FY core rev $280M

  Total revenue $71.7M, core revenue (ex-COVID) $71.7M, up 9% YoY.

• August 2, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Fulgent Q2 core revenue $70.2M (+5% YoY); GAAP loss $0.29/share improves EPS guidance

  Total revenue $71.0M; core revenue $70.2M (+5% YoY).

Materiality & sentiment trend

Max materiality 0.75 · Median 0.65 · Most common event earnings

6 positive 1 negative 10 neutral

source · FLGT on sec.gov